Option Care Health, Inc. (NASDAQ:OPCH) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Option Care Health, Inc. has received an average rating of "Moderate Buy" from nine analysts, with eight ratings for buy and one for hold, and an average price target of $35.75.
• Recent insider purchases include Director Harry M. Jansen Kraemer, Jr. acquiring 36,000 shares and Director Timothy P. Sullivan purchasing 20,000 shares, indicating strong insider confidence in the company's stock.
• Option Care Health reported a 15.4% increase in quarterly revenue year-over-year, achieving $1.42 billion, and surpassed earnings expectations with $0.41 per share compared to the consensus estimate of $0.40.

Shares of Option Care Health, Inc. (NASDAQ:OPCH - Get Free Report) have been given an average rating of "Moderate Buy" by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $35.75.

OPCH has been the subject of a number of research analyst reports. Barrington Research restated an "outperform" rating and set a $38.00 price objective on shares of Option Care Health in a research report on Tuesday. JMP Securities lifted their price target on Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a research report on Thursday, July 31st. Finally, Citigroup reiterated an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st.

Insider Buying and Selling

In related news, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The stock was bought at an average price of $27.15 per share, for a total transaction of $977,400.00. Following the completion of the transaction, the director owned 375,390 shares in the company, valued at approximately $10,191,838.50. The trade was a 10.61% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Timothy P. Sullivan purchased 20,000 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The stock was bought at an average price of $27.51 per share, with a total value of $550,200.00. Following the transaction, the director owned 49,229 shares of the company's stock, valued at $1,354,289.79. This represents a 68.43% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 59,411 shares of company stock worth $1,627,576. Corporate insiders own 0.64% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. USA Financial Formulas purchased a new position in Option Care Health in the second quarter worth about $26,000. Northwestern Mutual Wealth Management Co. boosted its position in shares of Option Care Health by 1,492.9% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 892 shares of the company's stock valued at $31,000 after buying an additional 836 shares during the period. McIlrath & Eck LLC purchased a new position in shares of Option Care Health during the second quarter valued at approximately $37,000. Brooklyn Investment Group boosted its position in shares of Option Care Health by 186.6% during the first quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock valued at $42,000 after buying an additional 780 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Option Care Health during the second quarter valued at approximately $40,000. Hedge funds and other institutional investors own 98.05% of the company's stock.

Option Care Health Trading Down 0.7%

Shares of Option Care Health stock opened at $27.50 on Thursday. The firm has a market cap of $4.46 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 1.68 and a beta of 0.82. The business has a 50-day moving average price of $28.68 and a 200-day moving average price of $31.12. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.81. Option Care Health has a twelve month low of $21.39 and a twelve month high of $35.53.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.40 by $0.01. The firm had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The business's quarterly revenue was up 15.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.30 earnings per share. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. Equities research analysts anticipate that Option Care Health will post 1.22 EPS for the current fiscal year.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.